Codexis

CDXS

Market cap $242M

REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York.

Codexis, Inc. (NASDAQ:CDXS ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Georgia L. Erbez - Chief Financial Officer Kevin Norrett - Chief Operating Officer Stephen George Dilly - President, CEO & Chairman Conference Call Participants Allison Marie Bratzel - Piper Sandler & Co., Research Division Brendan Mychal Smith - TD Cowen, Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Operator Welcome to Codexis Second Quarter 2025 Earnings Conference Call.

Codexis (CDXS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.32 per share a year ago.

Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised via ATM facility and Innovatus loan to support expansion of ECO Synthesis REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York.

Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bratzel - Piper Sandler Dan Arias - Stifel Matthew Hewitt - Craig-Hallum Brendan Smith - TD Cowen Operator Greetings and welcome to the Codexis First Quarter 2025 Earnings Conference Call and webcast. At this time, all participants are in a listen-only mode.

Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.